- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07670923
Comparison of Hemodynamics and Respiratory Function Between Ciprofol and Propofol in Elderly Patients Undergoing Non-intubated General Anesthesia
Обзор исследования
Статус
Вмешательство/лечение
Подробное описание
Inclusion Criteria
- Patients scheduled for elective non-intubated general anesthesia
- Age ranging from 65 to 80 years old
- American Society of Anesthesiologists (ASA) physical status class I-III
- Written informed consent signed by the patient or legal guardian
Exclusion Criteria
- Confirmed allergy to propofol, ciprofol or their excipients
- Severe cardiovascular diseases (uncontrolled hypertension, heart failure, severe arrhythmia, etc.)
- Severe respiratory diseases (chronic obstructive pulmonary disease, obstructive sleep apnea syndrome, etc.)
- Severe hepatic or renal insufficiency
- Long-term regular use of sedatives or opioids
- Baseline bradycardia (HR < 50 beats/min) or hypoxemia (SpO₂ < 90%) Elimination Criteria
1. Patients with allergic reactions to study drugs or other severe complications during the trial
2. Severe hypoxemia requiring emergency endotracheal intubation
3. Severe hemodynamic instability occurring during induction
4. Incomplete monitoring data caused by equipment malfunction Randomization and Group Allocation A total of 108 eligible elderly patients undergoing elective non-intubated general anesthesia at the Cardiovascular and Cerebrovascular Disease Hospital, General Hospital of Ningxia Medical University will be recruited. A computer-generated random number sequence will allocate subjects at a 1:1 ratio into the ciprofol group (Group C) and the propofol group (Group P).
Observation Indicators
Baseline Demographic Data
Gender, age, height, weight, BMI, ASA classification, smoking history, alcohol consumption, underlying diseases, Modified Mallampati score, thyromental distance, snoring history, etc.
Primary Observation Indicators
Hemodynamic parameters (Heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), cardiac output (CO), stroke volume (SV), systemic vascular resistance (SVR)) and respiratory parameters (peripheral oxygen saturation (SpO₂), respiratory rate (RR), end-tidal carbon dioxide (EtCO₂)) will be recorded at baseline, loss of consciousness, 30 s, 1 min, 2 min, 3 min, 4 min and 5 min after loss of consciousness.
Secondary Observation Indicators
- Baseline BIS value and minimum BIS value during induction
- Total induction dosage, induction time (from drug administration to MOAA/S ≤ 1), recovery time (from last drug administration to MOAA/S = 5)
- Incidence of adverse reactions: injection pain, involuntary movement, hiccup, hypotension, bradycardia, hypoventilation, apnea, hypoxemia, etc.
Anesthetic Protocol
All patients fast for 8 hours and abstain from clear liquids for 4 hours preoperatively. After entering the operating room, oxygen inhalation is initiated, upper limb venous access is established, and monitors including pulse oximetry, sidestream PETCO₂ monitor, continuous non-invasive arterial blood pressure monitor and bispectral index (BIS) monitor are connected.
Midazolam 0.01 mg/kg is administered intravenously first; stable circulatory and respiratory readings thereafter serve as baseline values. Ciprofol or propofol is then infused intravenously at 10 mL/min. Sedation depth is assessed every 5 seconds via MOAA/S scale; drug infusion is stopped once MOAA/S ≤ 1 (loss of consciousness). The total induction dose is recorded. All hemodynamic and respiratory indicators are documented at predefined time points.
Anesthesiologists may supplement 1/3 of the initial induction dose if the patient shows eye opening, verbal response or body movement, with an interval of at least 1 minute between supplemental doses.
Rescue Management Protocols
- Hypotension (SBP < 90 mmHg or MAP decreased by >20% from baseline lasting >2 min): ephedrine 6 mg IV
- Severe bradycardia (HR < 45 beats/min lasting >30 s): atropine 0.5 mg IV
- Hypoventilation (RR < 8 bpm, PETCO₂ less than half baseline or PETCO₂ ≥45 mmHg lasting >30 s)
- Apnea (no thoracic movement or flat PETCO₂ waveform lasting >10 s)
- Hypoxemia (SpO₂ < 93%) / severe hypoxemia (SpO₂ < 85%) For respiratory compromise, jaw thrust, increased oxygen flow or mask-assisted ventilation will be applied; emergency endotracheal intubation will be performed if necessary.
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 4
Контакты и местонахождение
Контакты исследования
- Имя: Hanxiang Ma Ma, master
- Номер телефона: 13519591508
- Электронная почта: mahanxiang@hotmail.com
Учебное резервное копирование контактов
- Имя: LI Mo Mo, Bachelor
- Номер телефона: 17752025907
- Электронная почта: ml185030153@163.com
Места учебы
-
-
Ningxia
-
Yinchuan, Ningxia, Китай, 750000
- Рекрутинг
- Cardiovascular and Cerebrovascular Disease Hospital, General Hospital of Ningxia Medical University
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
- Пожилой взрослый
Принимает здоровых добровольцев
Описание
Inclusion Criteria:
- Patients scheduled for elective non-intubated general anesthesia
- Age ranging from 65 to 80 years old
- American Society of Anesthesiologists (ASA) physical status class I-III
- Written informed consent signed by the patient or legal guardian
Exclusion Criteria:
- Confirmed allergy to propofol, ciprofol or their excipients
- Severe cardiovascular diseases (uncontrolled hypertension, heart failure, severe arrhythmia, etc.)
- Severe respiratory diseases (chronic obstructive pulmonary disease, obstructive sleep apnea syndrome, etc.)
- Severe hepatic or renal insufficiency
- Long-term regular use of sedatives or opioids
- Baseline bradycardia (HR < 50 beats/min) or hypoxemia (SpO₂ < 90%)
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Четырехместный
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Ciprofol treatment group
This group plans to enroll a total of 54 elderly patients aged 65-80 who will undergo brief procedures without intubation, using spontaneous respiration under general anesthesia.
The intravenous infusion of cyclopropane hydrochloride injection will be administered at a constant rate of 10 ml/min.
The administration will cease when the MOAA/S score is ≤1.
Throughout the procedure, hemodynamic parameters (HR, SBP, DBP, MAP, CO, SV,SVR), and respiratory parameters (SpO₂, respiratory rate (RR), PETCO₂), and various anesthetic adverse reactions will be monitored within the first 5 minutes after induction.
The safety of the medication will be evaluated in comparison with the control group
|
Intravenous administration, injection rate of 10 ml/min, continuous and uniform infusion until the patient's MOAA/S sedation score is ≤1 point.
This is used for the induction of general anesthesia in short-duration medical procedures for elderly individuals aged 65-80 without intubation and with spontaneous respiration
|
|
Активный компаратор: Propofol Control group
This study aims to enroll 54 elderly patients aged 65-80 with short procedures and no need for intubation, who will receive propofol intravenously at a constant rate of 10 ml/min until their MOAA/S score drops to ≤1 point.
Circulatory and respiratory parameters, as well as adverse events, will be recorded simultaneously 5 minutes after induction.
This will allow for a parallel comparison of the two medications' effects on the circulatory and respiratory systems of elderly patients with the propofol control group.
|
Intravenous administration, injection rate of 10 ml/min, continuous and uniform infusion until the patient's MOAA/S sedation score is ≤1 point.
This is used for the induction of general anesthesia in short-duration medical procedures for elderly individuals aged 65-80 without intubation and with spontaneous respiration
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Comparison of hemodynamic and respiratory function changes within 5 minutes of anesthesia induction
Временное ограничение: 5 minutes after induction of anesthesia
|
The primary objective of this study was to evaluate the degree of circulatory and respiratory suppression induced by two types of anesthesia drugs in elderly patients.
Continuous, non-invasive monitoring was conducted on the baseline conditions before administration for patients aged 65 to 80 undergoing short procedures without intubation and with spontaneous respiration under general anesthesia.
Additionally, measurements were taken at 1 minute, 2 minutes, 3 minutes, 4 minutes, and 5 minutes after induction to assess circulatory and respiratory functions.
Statistical analysis was performed to compare the changes in Heart rate, systolic blood pressure, diastolic blood pressure, mean arterial pressure, cardiac output , stroke volume, systemic vascular resistance , peripheral oxygen saturation, respiratory rate , end-tidal carbon dioxid within the 5-minute induction period.
A comprehensive assessment of the dual safety of circulatory and respiratory systems was conducted
|
5 minutes after induction of anesthesia
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Brain electrical activity sedation depth (BIS)
Временное ограничение: 5 minutes after induction of anesthesia
|
lowest BIS value throughout the induction process, BIS value immediately upon loss of consciousness.
|
5 minutes after induction of anesthesia
|
|
incidence of induction period circulatory/respiratory adverse events
Временное ограничение: 5 minutes after induction of anesthesia
|
Proportion of adverse events, including low blood pressure, bradycardia, inadequate ventilation, apnea, and hypoxemia, occurring within 5 minutes of induction
|
5 minutes after induction of anesthesia
|
Соавторы и исследователи
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Патологические процессы
- Заболевания дыхательных путей
- Нарушения дыхания
- Патологические состояния, признаки и симптомы
- Респираторная аспирация
- Органические химические вещества
- Углеводороды
- Углеводороды, циклические
- Углеводороды, ароматные
- Фенолы
- Бензольные производные
- Пропофол
- (2- (1R) -1-циклопропил) этил-6-изопропил-фенол
Другие идентификационные номера исследования
- Li Mo-2026-06-22
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .